The x c − cystine/glutamate antiporter as a potential therapeutic target for small-cell lung cancer: use of sulfasalazine (original) (raw)

Abstract

Purpose

To determine whether the x −c cystine transporter could be a useful therapeutic target for small-cell lung cancer (SCLC).

Methods

Human SCLC cell cultures were examined for growth dependence on extracellular cystine, x −c expression, glutathione levels and response to highly specific x −c inhibitors, i.e., monosodium glutamate (MSG) and the anti-inflammatory drug, sulfasalazine (SASP). In studying tumor growth inhibition by SASP, use was also made of a novel SCLC tissue xenograft model, LU6-SCLC, derived from a chemoresistant patient’s SCLC specimen.

Results

Growth of NCI-H69 and NCI-H82 SCLC cells greatly depended on x −c -mediated uptake of cystine. SASP substantially reduced their glutathione levels (>70%; 0.3 mM SASP; 24 h) and growth (72 h) with IC50s of 0.21 and 0.13 mM, respectively; MSG also inhibited growth markedly. Both SASP- and MSG-induced growth arrests were largely prevented by cystine uptake-enhancing 2-mercaptoethanol (66 μM) indicating they were primarily due to cystine starvation. Without major side-effects, SASP (i.p.) restrained growth of NCI-H69 cell xenografts (~50%) and, importantly, substantially inhibited growth of the clinically more relevant LU6-SCLC tissue xenografts (~70% by stereological analysis), reducing tumor glutathione contents.

Conclusions

The x −c cystine/glutamate antiporter is potentially useful as a target for therapy of SCLC based on glutathione depletion. Sulfasalazine may be readily used for this approach, especially in combination chemotherapy.

Access this article

Log in via an institution

Subscribe and save

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Sun S, Schiller JH, Spinola M, Minna JD (2007) New molecularly targeted therapies for lung cancer. J Clin Invest 117:2740–2750
    Article PubMed CAS Google Scholar
  2. Simon GR, Turrisi A (2007) Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 132:324S–339S
    Article PubMed CAS Google Scholar
  3. Hann CL, Rudin CM (2007) Fast, hungry and unstable: finding the Achilles’ heel of small-cell lung cancer. Trends Mol Med 13:150–157
    Article PubMed CAS Google Scholar
  4. Gout PW, Kang YJ, Buckley DJ, Bruchovsky N, Buckley AR (1997) Increased cystine uptake capability associated with malignant progression of Nb2 lymphoma cells. Leukemia 11:1329–1337
    Article PubMed CAS Google Scholar
  5. Gout PW, Buckley AR, Simms CR, Bruchovsky N (2001) Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x −c cystine transporter: a new action for an old drug. Leukemia 15:1633–1640
    Article PubMed CAS Google Scholar
  6. Narang VS, Pauletti GM, Gout PW, Buckley DJ, Buckley AR (2003) Suppression of cystine uptake by sulfasalazine inhibits proliferation of human mammary carcinoma cells. Anticancer Res 23:4571–4579
    PubMed CAS Google Scholar
  7. Doxsee DW, Gout PW, Kurita T, Lo M, Buckley AR, Wang Y, Xue H, Karp CM, Cutz JC, Cunha GR, Wang YZ (2007) Sulfasalazine-induced cystine starvation: potential use for prostate cancer therapy. Prostate 67:162–171
    Article PubMed CAS Google Scholar
  8. Lo M, Ling V, Wang YZ, Gout PW (2008) The x −c cystine/glutamate antiporter: a mediator of pancreatic cancer growth with a role in drug resistance. Br J Cancer 99:464–472
    Article PubMed CAS Google Scholar
  9. Bannai S (1986) Exchange of cystine and glutamate across plasma membrane of human fibroblasts. J Biol Chem 261:2256–2263
    PubMed CAS Google Scholar
  10. Gout PW, Simms CR, Robertson MC (2003) In vitro studies on the lymphoma growth-inhibitory activity of sulfasalazine. Anticancer Drugs 14:21–29
    Article PubMed CAS Google Scholar
  11. Lo M, Wang YZ, Gout PW (2008) The x −c cystine/glutamate antiporter: a potential target for therapy of cancer and other diseases. J Cell Physiol 215:593–602
    Article PubMed CAS Google Scholar
  12. Edinger AL, Thompson CB (2002) Antigen-presenting cells control T cell proliferation by regulating amino acid availability. Proc Natl Acad Sci USA 99:1107–1109
    Article PubMed CAS Google Scholar
  13. Estrela JM, Ortega A, Obrador E (2006) Glutathione in cancer biology and therapy. Crit Rev Clin Lab Sci 43:143–181
    Article PubMed CAS Google Scholar
  14. Griffith OW (1999) Biologic and pharmacologic regulation of mammalian glutathione synthesis. Free Radic Biol Med 27:922–935
    Article PubMed CAS Google Scholar
  15. Narang VS, Pauletti GM, Gout PW, Buckley DJ, Buckley AR (2007) Sulfasalazine-induced reduction of glutathione levels in breast cancer cells: enhancement of growth-inhibitory activity of doxorubicin. Chemotherapy 53:210–217
    Article PubMed CAS Google Scholar
  16. Voskoglou-Nomikos T, Pater JL, Seymour L (2003) Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res 9:4227–4239
    PubMed Google Scholar
  17. Sharpless NE, Depinho RA (2006) The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov 5:741–754
    Article PubMed CAS Google Scholar
  18. Wang Y, Xue H, Cutz JC, Bayani J, Mawji NR, Chen WG, Goetz LJ, Hayward SW, Sadar MD, Gilks CB, Gout PW, Squire JA, Cunha GR, Wang YZ (2005) An orthotopic metastatic prostate cancer model in SCID mice via grafting of a transplantable human prostate tumor line. Lab Invest 85:1392–1404
    Article PubMed Google Scholar
  19. Cutz JC, Guan J, Bayani J, Yoshimoto M, Xue H, Sutcliffe M, English J, Flint J, LeRiche J, Yee J, Squire JA, Gout PW, Lam S, Wang YZ (2006) Establishment in severe combined immunodeficiency mice of subrenal capsule xenografts and transplantable tumor lines from a variety of primary human lung cancers: potential models for studying tumor progression-related changes. Clin Cancer Res 12:4043–4054
    Article PubMed CAS Google Scholar
  20. Mayhew TM (1991) The new stereological methods for interpreting functional morphology from slices of cells and organs. Exp Physiol 76:639–665
    PubMed CAS Google Scholar
  21. Howard CV, Reed MG (2005) Unbiased stereology. Bios Scientific Publishers, Oxford, pp 256–277
    Google Scholar
  22. Dockery P, Fraher J (2007) The quantification of vascular beds: a stereological approach. Exp Mol Pathol 82:110–120
    Article PubMed CAS Google Scholar
  23. Rosado JO, Salvador M, Bonatto D (2007) Importance of the trans-sulfuration pathway in cancer prevention and promotion. Mol Cell Biochem 301:1–12
    Article PubMed CAS Google Scholar
  24. Uren JR, Lazarus H (1979) l-cyst(e)ine requirements of malignant cells and progress toward depletion therapy. Cancer Treat Rep 63:1073–1079
    PubMed CAS Google Scholar
  25. Verrey F, Closs EI, Wagner CA, Palacin M, Endou H, Kanai Y (2004) CATs and HATs: the SLC7 family of amino acid transporters. Pflugers Arch 447:532–542
    Article PubMed CAS Google Scholar
  26. Ishii T, Bannai S, Sugita Y (1981) Mechanism of growth stimulation of L1210 cells by 2-mercaptoethanol in vitro. Role of the mixed disulfide of 2-mercaptoethanol and cysteine. J Biol Chem 256:12387–12392
    PubMed CAS Google Scholar
  27. Guastavino E, Litwin NH, Heffes Nahmod L, Licastro R (1988) Ulcerative colitis in children. Levels of salicylazosulfapyridine and sulfapyridine during treatment. Acta Gastroenterol Latinoam 18:107–113
    PubMed CAS Google Scholar
  28. Gmunder H, Eck HP, Droge W (1991) Low membrane transport activity for cystine in resting and mitogenically stimulated human lymphocyte preparations and human T cell clones. Eur J Biochem 201:113–117
    Article PubMed CAS Google Scholar
  29. Klotz U (1985) Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. Clin Pharmacokinet 10:285–302
    Article PubMed CAS Google Scholar
  30. Chung WJ, Lyons SA, Nelson GM, Hamza H, Gladson CL, Gillespie GY, Sontheimer H (2005) Inhibition of cystine uptake disrupts the growth of primary brain tumors. J Neurosci 25:7101–7110
    Article PubMed CAS Google Scholar
  31. Rodenburg RJ, Ganga A, van Lent PL, van de Putte LB, van Venrooij WJ (2000) The antiinflammatory drug sulfasalazine inhibits tumor necrosis factor alpha expression in macrophages by inducing apoptosis. Arthritis Rheum 43:1941–1950
    Article PubMed CAS Google Scholar
  32. Bingle L, Brown NJ, Lewis CE (2002) The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 196:254–265
    Article PubMed CAS Google Scholar
  33. Lay JD, Hong CC, Huang JS, Yang YY, Pao CY, Liu CH, Lai YP, Lai GM, Cheng AL, Su IJ, Chuang SE (2007) Sulfasalazine suppresses drug resistance and invasiveness of lung adenocarcinoma cells expressing AXL. Cancer Res 67:3878–3887
    Article PubMed CAS Google Scholar
  34. Wahl C, Liptay S, Adler G, Schmid RM (1998) Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 101:1163–1174
    Article PubMed CAS Google Scholar
  35. Schnelldorfer T, Gansauge S, Gansauge F, Schlosser S, Beger HG, Nussler AK (2000) Glutathione depletion causes cell growth inhibition and enhanced apoptosis in pancreatic cancer cells. Cancer 89:1440–1447
    Article PubMed CAS Google Scholar
  36. Davison K, Cote S, Mader S, Miller WH (2003) Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines. Leukemia 17:931–940
    Article PubMed CAS Google Scholar
  37. Huang Y, Dai Z, Barbacioru C, Sadee W (2005) Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance. Cancer Res 65:7446–7454
    Article PubMed CAS Google Scholar

Download references

Acknowledgments

The authors thank Dan Doxsee, Hui Xue, Margaret Sutcliffe and Lily Wei for technical assistance. This study was financially supported by grants from the National Cancer Institute of Canada and British Columbia Lung Association (Y.Z.W), Canadian Institutes of Health Research (P.W.G/Y.Z), BC Cancer Foundation (P.W.G), Genome Canada (S.L) and National Breast Cancer Institute of Ireland (S.M). ML was supported by Sr. Graduate Studentship Awards from the Natural Sciences and Engineering Research Council of Canada, Canadian Institutes of Health Research and Michael Smith Foundation for Health Research

Conflict of interest statement

None.

Author information

Authors and Affiliations

  1. Department of Cancer Endocrinology, BC Cancer Agency, Research Centre, 675 West 10th Avenue, Vancouver, BC, V5Z 1L3, Canada
    Jun Guan, Peter W. Gout & Yu-Zhuo Wang
  2. Department of Cancer Genetics, BC Cancer Agency, Research Centre, Vancouver, BC, V5Z 1L3, Canada
    Maisie Lo
  3. Department of Anatomy, National University of Ireland, Galway, Ireland
    Peter Dockery
  4. Department of Surgery, National University of Ireland, Galway, Ireland
    Sarah Mahon
  5. Center for Advanced Biotechnology and Medicine, Rutgers University, Piscataway, NJ, 08854, USA
    Cristina M. Karp
  6. James L. Winkle College of Pharmacy, University of Cincinnati Academic Health Center, Cincinnati, OH, 45267-0004, USA
    Arthur R. Buckley
  7. Department of Cancer Imaging, BC Cancer Agency, Research Centre, Vancouver, BC, V5Z 1L3, Canada
    Stephen Lam
  8. The Prostate Centre at Vancouver General Hospital and Department of Urologic Sciences, University of BC, Vancouver, BC, V6T 2B5, Canada
    Yu-Zhuo Wang

Authors

  1. Jun Guan
    You can also search for this author inPubMed Google Scholar
  2. Maisie Lo
    You can also search for this author inPubMed Google Scholar
  3. Peter Dockery
    You can also search for this author inPubMed Google Scholar
  4. Sarah Mahon
    You can also search for this author inPubMed Google Scholar
  5. Cristina M. Karp
    You can also search for this author inPubMed Google Scholar
  6. Arthur R. Buckley
    You can also search for this author inPubMed Google Scholar
  7. Stephen Lam
    You can also search for this author inPubMed Google Scholar
  8. Peter W. Gout
    You can also search for this author inPubMed Google Scholar
  9. Yu-Zhuo Wang
    You can also search for this author inPubMed Google Scholar

Corresponding authors

Correspondence toPeter W. Gout or Yu-Zhuo Wang.

Rights and permissions

About this article

Cite this article

Guan, J., Lo, M., Dockery, P. et al. The x −c cystine/glutamate antiporter as a potential therapeutic target for small-cell lung cancer: use of sulfasalazine.Cancer Chemother Pharmacol 64, 463–472 (2009). https://doi.org/10.1007/s00280-008-0894-4

Download citation

Keywords